Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis

Resminostat, a novel class I, IIb, and IV histone deacetylase inhibitor, was studied in advanced hepatocellular carcinoma (HCC) patients after relapse to sorafenib (SHELTER study). In this phase I/II clinical trial, combination of sorafenib and resminostat was safe and showed early signs of efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Soukupova, Jitka, Bertran, Esther, Peñuelas-Haro, Irene, Urdiroz-Urricelqui, Uxue, Borgman, Matthias, Kohlhof, Hella, Fabregat, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746389/
https://www.ncbi.nlm.nih.gov/pubmed/29299154
http://dx.doi.org/10.18632/oncotarget.22775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746389/
https://www.ncbi.nlm.nih.gov/pubmed/29299154
http://dx.doi.org/10.18632/oncotarget.22775

Ejemplares similares